Aerosol Delivery Devices Market Research Report In 2019, the aerosol delivery devices market is projected to reach $46.73 billion by 2027, ...
aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders ...
A protein called Runx2 contributes to the abnormal activity of lung cells that drive pulmonary fibrosis, a new study shows.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback